Taking into account that E-cadherin is routinely assessed in pathology departments as diagnostic tool for other cancer types (60), it would be easy to implement it as biomarker of response to SRLs to better define acromegaly treatment (61). This evidence concerns the gene CDH1 and acromegaly.